CSRC approves HegenBio's application for IPO registration on the Science and Technology Innovation Board.

On July 18th, the China Securities Regulatory Commission issued a reply approving the initial public offering of shares by Wuhan Heyuan Biotechnology Co., Ltd. It is reported that Heyuan Bio intends to list on the Shanghai Stock Exchange's Sci-Tech innovation board, with Guotai Haitong as its sponsor institution, aiming to raise 2.4 billion yuan. According to the prospectus, Heyuan Bio is an innovative biopharmaceutical company with a globally leading plant bioreactor technology platform. The company has established an internationally leading, independently owned intellectual property rice endosperm cell bioreactor expression system, including the upstream technology rice endosperm cell bioreactor efficient recombinant protein expression platform (OryzHiExp) and downstream technology recombinant protein purification platform (OryzPur). In terms of production, the company's headquarters and R&D production base project are located in the Optics Valley Bio-city (Wuhan National Biotechnology Industry Base). The company has completed a commercial-scale production line with an annual output of 10 tons of OsrHSA raw material and formulated cGMP intelligent production line by 2023, and obtained a drug production license. At the same time, the company started construction in September 2024 of a new production line with an annual output of 120 tons of OsrHSA raw material cGMP intelligent production line and its supporting engineering facilities (the "Recombinant Human Albumin Industrialization Base Construction Project"), with a total land area of approximately 70,000 square meters.